---
search:
  boost: 3
---

# Lipotropics

This is a subcategory of Cardiovascular Agents.

## Decision Trees

- [Lipotropics- ATP Citrate Lyase (ACL) Inhibitors - Nexletol, Nexlizet](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUOFo5N05aUFVBVFY5SERQNVpTSjVNQVgwSyQlQCN0PWcu){ :target="_blank" rel="noopener"}

- [Lipotropics- Bile Acid Sequestrants – Colesevelam, Colestipol Granules](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUMUxSR0VUVzVLOEpOUlBEODhRTlVKODVGNyQlQCN0PWcu){ :target="_blank" rel="noopener"}

- [Lipotropics- Fibrates - Fenofibrate Cap, Fenofibrate 40, 54, 120, 160mg Tab, Fenofibric Acid](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUOUc4WUEzTzBBQTVTOEQ2SkFZQ0RWRzc2ViQlQCN0PWcu){ :target="_blank" rel="noopener"}

- [Lipotropics- HMG-CoA Reductase Inhibitors - Altoprev, Ezallor, Fluvastatin, Livalo, Zypitamag Amlodipine/Atorvastatin, Ezetimibe/Simvastatin](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUMTFHS1ZESkJXVk1IUlI3VkswUk0yNTdYVCQlQCN0PWcu){ :target="_blank" rel="noopener"}

- [Lipotropics - Juxtapid](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUNENWSlRHTko5MUNNVlU5SVRPVVBXNlZUVCQlQCN0PWcu){ :target="_blank" rel="noopener"}

- [Lipotropics- Niacin Derivatives - Niacin ER Tab](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUQlRWNDZDU0VCQkNWM0hMNFVGMDM5UEQxOSQlQCN0PWcu){ :target="_blank" rel="noopener"}

- [Lipotropics- Omega 3 Fatty Acids - Lovaza, Vascepa](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUNUVVUkVURkRWVEpVMjhLODNGWDMzTFdWWSQlQCN0PWcu){ :target="_blank" rel="noopener"}

- [Lipotropics- PCSK-9 Inhibitors- Praluent, Repatha](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUMVNHSEg4TFFJTDZIWkdTUFY4TVM3NlZXWiQlQCN0PWcu){ :target="_blank" rel="noopener"}

## Formulary

### Preferred

| Preferred                                  | Generic Name                              | Quantity | Time (Days) |
|:-------------------------------------------|:------------------------------------------|:--------:|:-----------:|
| Atorvastatin <sup>QL</sup>                 | Atorvastatin Calcium Tab (all strengths)  |   102    |     102     |
| Cholestyramine Regular, Light              |                                           |          |             |
| Colestipol Tab                             |                                           |          |             |
| Ezetimibe                                  |                                           |          |             |
| Fenofibrate 48 and 145mg Tab <sup>QL</sup> | Fenofibrate Tab 48 MG & 145 MG            |   102    |     102     |
| Gemfibrozil <sup>QL</sup>                  | Gemfibrozil Tab                           |   204    |     102     |
| Lovastatin <sup>QL</sup>                   | Lovastatin Tab (all strengths)            |   204    |     102     |
| Omega-3-Acid Ethyl Esters                  |                                           |          |             |
| Niacin IR, ER OTC <sup>QL</sup>            | Niacin ER Tab (all strengths excl 500 MG) |   204    |     102     |
| Niacin IR, ER OTC <sup>QL</sup>            | Niacin ER Tab 500 MG                      |   306    |     102     |
| Praluent <sup>PA</sup>                     |                                           |          |             |
| Pravastatin                                | Pravastatin Sodium (all strengths)        |   102    |     102     |
| Prevalite                                  |                                           |          |             |
| Repatha <sup>PA</sup>                      |                                           |          |             |
| Rosuvastatin <sup>QL</sup>                 | Rosuvastatin Calcium Tab (all strengths)  |   102    |     102     |
| Simvastatin <sup>QL</sup>                  | Simvastatin Tab (all strengths)           |   102    |     102     |

### Non-Preferred

| Non-Preferred                                       | Generic Name                                        |         Quantity          |        Time (Days)        |
|:----------------------------------------------------|:----------------------------------------------------|:-------------------------:|:-------------------------:|
| Altoprev                                            |                                                     |                           |                           |
| Amlodipine / Atorvastatin                           |                                                     |                           |                           |
| Colesevelam                                         |                                                     |                           |                           |
| Colestipol Granules                                 |                                                     |                           |                           |
| Ezetimibe / Simvastatin                             |                                                     |                           |                           |
| Ezallor                                             |                                                     |                           |                           |
| Fenofibrate Cap <sup>QL</sup>                       | Fenofibrate Cap (all strengths)                     | Determined pursuant to PA | Determined pursuant to PA |
| Fenofibrate 40, 54, 120 and 160mg Tab <sup>QL</sup> | Fenofibrate Tab (all strengths excl 48 MG & 145 MG) | Determined pursuant to PA | Determined pursuant to PA |
| Fenofibric Acid <sup>QL</sup>                       | Fenofibric Acid Tab (all strengths)                 | Determined pursuant to PA | Determined pursuant to PA |
| Fenofibric Acid DR <sup>QL</sup>                    | Choline Fenofibrate DR Cap (all strengths)          |            102            |            102            |
| Fluvastatin                                         |                                                     |                           |                           |
| Juxtapid                                            |                                                     |                           |                           |
| Livalo                                              |                                                     |                           |                           |
| Nexletol                                            |                                                     |                           |                           |
| Nexlizet                                            |                                                     |                           |                           |
| Niacin ER Tab <sup>QL</sup>                         | Niacin ER Tab (all strengths excl 200 MG)           |            204            |            102            |
| Niacin ER Tab <sup>QL</sup>                         | Niacin ER Tab 500 MG                                |            408            |            102            |
| Vascepa <sup>BvG ==(Process by NDC)==</sup>                            |                                                     |                           |                           |
| Zypitamag                                           |                                                     |                           |                           |

## Authorizations

**Length of Authorizations**: See below

|                                           |          |
|-------------------------------------------|----------|
| Juxtapid (Initial)                        | 180 days |
| Vascepa, Lovaza, ACL inhibitors (Initial) | 84 days  |
| All others (Initial and Subsequent)       | 365 days |

**All Authorizations**: Must be prescribed in accordance with FDA approved labeling

## Criteria

### Clinical PA

Clinical PA Criteria

- Must provide documentation of baseline labs **AND** have documented adherence to ^^90 days^^ of prescribed lipid lowering medications
- Must have had an inadequate clinical response of at least ^^90 days^^ **AND** unable to reach goal LDL-C (see below) despite treatment with maximally tolerated dose of highpotency statin and ezetimibe (or a clinical reason that these drugs cannot be utilized)

### Non-Preferred

Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response of at least ^^30 days^^ (or ^^90 days^^ for fibrates) with at least ^^one preferred^^ drug in the same drug class
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

### Lovastatin ER (Altoprev), Pitavastatin (Livalo), Fluvastatin (Lescol)

Additional Lovastatin ER (Altoprev), Pitavastatin (Livalo), Fluvastatin (Lescol) Criteria

- Must have had an inadequate clinical response of at least ^^30 days^^ with ^^two preferred^^ drugs in the same drug class

### Colesevelam (Welchol)

Additional Criteria for Colesevelam (Welchol)

- Must provide documentation of a Type 2 Diabetes diagnosis

### Icosapent Ethyl (Vascepa)

Additional Icosapent Ethyl (Vascepa) Criteria

- Must provide documentation of baseline labs indicating triglyceride levels ≥500mg/dL after an inadequate clinical response to fibrates, niacin, and diet/exercise
- Must provide documentation of discontinuation of drugs known to increase triglyceride levels (i.e., beta blockers, thiazides, and estrogens), if clinically appropriate

### Lomitapide (Juxtapid) & ATP Citrate Lysase (ACL) Inhibitor

Additional Lomitapide (Juxtapid) & ATP Citrate Lysase (ACL) Inhibitor Criteria

- Must provide documentation of baseline labs **AND** have documented adherence to ^^90 days^^ of prescribed lipid lowering medications
- Must have had inadequate clinical response of at least ^^90 days^^ **AND** unable to reach goal LDL-C with high-potency statin, ezetimibe and PCSK9 inhibitor (or a clinical reason that these drugs cannot be utilized)

### Additional Information

- High potency statins: atorvastatin (Lipitor) 40-80mg & rosuvastatin (Crestor) 20-40mg
- LDL goals for ^^Familial Hypercholesterolemia^^ (includes Heterozygous & Homozygous FH): LDL ≤ 100mg/dL for adults or LDL ≤ 110mg/dL for those < 18 years of age
- LDL goals for ^^Clinical Atherosclerotic Cardiovascular Disease (ASCVD)^^: LDL ≤ 70mg/dL

### Subsequent Authorization

Subsequent Authorization Criteria

- Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring

## Links

[Denial Language (Rph Use Only: Technicians CANNOT deny Prior Authorizations)](https://mygainwell-my.sharepoint.com.mcas.ms/:w:/r/personal/rachel_carpenter_gainwelltechnologies_com/_layouts/15/Doc.aspx?sourcedoc=%7BCD777F63-7F18-4713-8D6A-B043BEE631F5%7D&file=Denial%20Language%20Updated%2009112023.docx&action=embedview&mobileredirect=true&wdStartOn=17&cid=f4472ece-6d4f-4694-b0c5-c150a2f53fea){:target="_blank" rel="noopener"}

[Criteria](https://medicaid.ohio.gov/static/PHM/drug-coverage/20230701+UPDL+Criteria+_v1_FINAL.approved.pdf#page=22){ :target="_blank" rel="noopener"}

[Preferred Drug List](https://medicaid.ohio.gov/static/PHM/drug-coverage/20230701_UPDL_FINAL_ODM.approved.v2.pdf#page=12){ :target="_blank" rel="noopener"}

[Quantity Limit List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_Ohio_Medicaid_Quantity_Document_APPROVED.pdf){ :target="_blank" rel="noopener"}
